Skip to main content
SpringerLink
Log in

Role of Hepatic Artery Infusion Pump Chemotherapy for Unresectable Colorectal Cancer Liver Metastases

  • Chapter
  • First Online:
Book cover Colorectal Cancer Liver Metastases

Abstract

Although liver metastasis develops in over half of patients with colorectal cancer, only 15–20% of these patients are resectable at presentation. Moreover, patients with unresectable colorectal liver metastasis (CRLM) who progress on first-line systemic chemotherapy have limited treatment options. Hepatic arterial infusion chemotherapy (HAIC), in combination with systemic chemotherapy, leverages a multimodality approach to achieving hepatic disease control and/or expanding resectability in patients with liver-dominant disease. Intra-arterial delivery of agents with high first-pass hepatic extraction (e.g., floxuridine [FUDR]) limits systemic toxicity and allows for administration of systemic chemotherapy at near-full doses. HAIC in conjunction with systemic chemotherapy augments response rates up to 92% in chemotherapy-naive, and up to 85% in pretreated, patients with unresectable CRLM. In turn, these responses translate into encouraging rates of conversion to resectability (CTR). Prospective trials of HAIC have reported CTR rates as high as 52% in heavily pretreated patients with extensive hepatic disease burden. As such, CTR is a compelling indication for liver-directed chemotherapy in this subset of patients. This chapter discusses the rationale for HAIC, evolution of rational combinations with systemic chemotherapy, contemporary evidence for CTR using HAIC and systemic chemotherapy, juxtaposition with CTR rates using systemic chemotherapy alone, and the morbidity and toxicity profiles of HAI chemotherapy. Finally, the argument is made for consideration of both earlier initiation of HAIC in chemotherapy-naive patients with unresectable CRLM and adoption of HAIC strategies to augment resectability rates in patients who have failed first-line systemic chemotherapy before proceeding to second-/third-line regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

FOLFIRI:

5-FU, leucovorin, irinotecan

FOLFOX:

5-FU, leucovorin, oxaliplatin

FOLFOXIRI:

5-FU, leucovorin, oxaliplatin, irinotecan

References

  1. American Cancer Society: Key Statistics for Colorectal Cancer. 2017; Available from: www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics.

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.

    Article  PubMed  Google Scholar 

  3. Tomlinson JS, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80.

    Article  PubMed  Google Scholar 

  4. Adam R, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27(11):1829–35.

    Article  PubMed  Google Scholar 

  5. Saltz LB, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–14.

    Article  PubMed  CAS  Google Scholar 

  6. de Gramont A, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.

    Article  PubMed  Google Scholar 

  7. Tournigand C, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.

    Article  PubMed  CAS  Google Scholar 

  8. Cunningham D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45.

    Article  PubMed  CAS  Google Scholar 

  9. Hurwitz HI, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23(15):3502–8.

    Article  PubMed  CAS  Google Scholar 

  10. Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–34.

    Article  PubMed  CAS  Google Scholar 

  11. Alberts SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23(36):9243–9.

    Article  PubMed  CAS  Google Scholar 

  12. Folprecht G, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014;25(5):1018–25.

    Article  PubMed  CAS  Google Scholar 

  13. Masi G, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420–5.

    Article  PubMed  Google Scholar 

  14. Lam VW, et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol. 2012;19(4):1292–301.

    Article  PubMed  Google Scholar 

  15. Mokdad A, Choti MA, Yopp AC. Conversion chemotherapy for unresectable colorectal liver metastases: are we making a difference? Curr Colorectal Cancer Rep. 2015;11(4):160–7.

    Article  Google Scholar 

  16. Sanoff HK, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26(35):5721–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Peeters M, et al. Final results from a randomized phase 3 study of FOLFIRI {+/−} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(1):107–16.

    Article  PubMed  CAS  Google Scholar 

  18. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969–77.

    PubMed  PubMed Central  CAS  Google Scholar 

  19. Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983;10(2):176–82.

    PubMed  CAS  Google Scholar 

  20. Ducreux M, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23(22):4881–7.

    Article  PubMed  CAS  Google Scholar 

  21. Shimonov M, et al. Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver. Chemotherapy. 2005;51(2–3):111–5.

    Article  PubMed  CAS  Google Scholar 

  22. Kemeny N, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer. 1992;69(2):327–34.

    Article  PubMed  CAS  Google Scholar 

  23. Kemeny MM, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol. 2002;20(6):1499–505.

    PubMed  Google Scholar 

  24. Kemeny N, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039–48.

    Article  PubMed  CAS  Google Scholar 

  25. Kemeny N, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987;107(4):459–65.

    Article  PubMed  CAS  Google Scholar 

  26. Kerr DJ, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet. 2003;361(9355):368–73.

    Article  PubMed  CAS  Google Scholar 

  27. Rougier P, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10(7):1112–8.

    Article  PubMed  CAS  Google Scholar 

  28. Mocellin S, et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007;25(35):5649–54.

    Article  PubMed  Google Scholar 

  29. D'Angelica M, et al. Hepatic arterial infusion chemotherapy for metastases from colorectal cancer: is it really the end of an era? J Clin Oncol. 2008;26(16):2788–9; author reply 2789-90.

    Article  PubMed  Google Scholar 

  30. Kemeny NE, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395–403.

    Article  PubMed  CAS  Google Scholar 

  31. Fiorentini G, et al. Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study. In Vivo. 2006;20(6A):707–9.

    PubMed  CAS  Google Scholar 

  32. Kemeny N, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol. 2001;19(10):2687–95.

    Article  PubMed  CAS  Google Scholar 

  33. Kemeny N, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23(22):4888–96.

    Article  PubMed  CAS  Google Scholar 

  34. Li C, et al. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Cancer Chemother Pharmacol. 2014;74(5):1079–87.

    Article  PubMed  CAS  Google Scholar 

  35. Kemeny NE, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465–71.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Grothey A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12.

    Article  PubMed  CAS  Google Scholar 

  37. Mayer RJ, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–19.

    Article  PubMed  Google Scholar 

  38. Cercek A, et al. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. J Surg Oncol. 2016;114(6):655–63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Dhir M, et al. Hepatic arterial infusion in combination with modern systemic chemotherapy is associated with improved survival compared with modern systemic chemotherapy alone in patients with isolated unresectable colorectal liver metastases: a case-control study. Ann Surg Oncol. 2017;24(1):150–8.

    Article  PubMed  Google Scholar 

  40. Karanicolas PJ, Ko YJ. Hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the dawn of a new era? Ann Surg Oncol. 2017;24(1):6–7.

    Article  PubMed  Google Scholar 

  41. Kemeny NE, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol. 2011;29(7):884–9.

    Article  PubMed  CAS  Google Scholar 

  42. Levi FA, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2016;27(2):267–74.

    Article  PubMed  CAS  Google Scholar 

  43. Sperling J, et al. Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases. Int J Color Dis. 2013;28(4):555–62.

    Article  Google Scholar 

  44. Connell LC, et al. Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases. J Surg Oncol. 2017;115(4):480–7.

    Article  PubMed  CAS  Google Scholar 

  45. Folprecht G, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16(8):1311–9.

    Article  PubMed  CAS  Google Scholar 

  46. Kelly CM, Kemeny NE. Liver-directed therapy in metastatic colorectal cancer. Expert Rev Anticancer Ther. 2017;17(8):745–58.

    Article  PubMed  CAS  Google Scholar 

  47. Ammori JB, et al. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. Ann Surg Oncol. 2013;20(9):2901–7.

    Article  PubMed  Google Scholar 

  48. D'Angelica MI, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261(2):353–60.

    Article  PubMed  Google Scholar 

  49. Pak LM, et al. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: long term results and curative potential. J Surg Oncol. 2018;117(4):634–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Goere D, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251(4):686–91.

    Article  PubMed  Google Scholar 

  51. Barone C, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97(8):1035–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Giacchetti S, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10(6):663–9.

    Article  PubMed  CAS  Google Scholar 

  53. Folprecht G, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47.

    Article  PubMed  CAS  Google Scholar 

  54. Allen PJ, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201(1):57–65.

    Article  PubMed  Google Scholar 

  55. Kanat O, Gewirtz A, Kemeny N. What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer. J Gastrointest Oncol. 2012;3(2):130–8.

    PubMed  PubMed Central  CAS  Google Scholar 

  56. Ito K, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol. 2012;19(5):1609–17.

    Article  PubMed  Google Scholar 

  57. Allen-Mersh TG, et al. Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases. Eur J Surg Oncol. 2000;26(5):468–73.

    Article  PubMed  CAS  Google Scholar 

  58. Fallik D, et al. Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. Ann Oncol. 2003;14(6):856–63.

    Article  PubMed  CAS  Google Scholar 

  59. Mancini R, et al. Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases. Anticancer Res. 2003;23(2C):1837–41.

    PubMed  CAS  Google Scholar 

  60. Tsutsumi S, et al. Hepatic arterial infusion combined with oral UFT/UZEL systemic chemotherapy for unresectable liver metastasis of colorectal cancer. Hepato-Gastroenterology. 2008;55(85):1419–22.

    PubMed  CAS  Google Scholar 

  61. Idelevich E, et al. Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. Chemotherapy. 2009;55(2):76–82.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Jashodeep Datta & Michael I. D’Angelica

  2. The Dewitt Daughtry Family Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

    Jashodeep Datta

  3. Memorial Sloan Kettering Cancer Center, Weill Cornell Unviersity School of Medicine, Miami, FL, USA

    Jashodeep Datta

Authors
  1. Jashodeep Datta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael I. D’Angelica
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael I. D’Angelica .

Editor information

Editors and Affiliations

  1. National Cancer Institute, Rio de Janeiro, Brazil

    Mauro Monteiro Correia

  2. Banner MD Anderson Cancer Center, Phoenix, AZ, USA

    Michael A. Choti

  3. Virginia Mason Medical Center, Seattle, WA, USA

    Flavio G. Rocha

  4. Center for Advanced Treatment of HBP Diseases, Ageo Central General Hospital, Ageo Shi, Saitama, Japan

    Go Wakabayashi

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Datta, J., D’Angelica, M.I. (2020). Role of Hepatic Artery Infusion Pump Chemotherapy for Unresectable Colorectal Cancer Liver Metastases. In: Correia, M., Choti, M., Rocha, F., Wakabayashi, G. (eds) Colorectal Cancer Liver Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-25486-5_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25486-5_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25485-8

  • Online ISBN: 978-3-030-25486-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation